These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 37965924)

  • 41. Adjuvant chemotherapy following combined induction chemotherapy and concurrent chemoradiotherapy improves survival in N2-3-positive nasopharyngeal carcinoma patients.
    Tao HY; Liu H; He F; He CX; Li R; Du KP; Yuan YW; Zheng RH
    J Cancer Res Clin Oncol; 2022 Nov; 148(11):2959-2969. PubMed ID: 34822015
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Concurrent chemoradiotherapy combined with nimotuzumab in stage III-IVa nasopharyngeal carcinoma: a retrospective analysis.
    Cai Z; Chen D; Qiu W; Liang C; Huang Y; Zhou J; Zhan Z; Xiang Y; Guo X; Lv X
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2327-2344. PubMed ID: 36289067
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Beneficial effects of anti-EGFR agents, Cetuximab or Nimotuzumab, in combination with concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma.
    Lin M; You R; Liu YP; Zhang YN; Zhang HJ; Zou X; Yang Q; Li CF; Hua YJ; Yu T; Cao JY; Li JB; Mo HY; Guo L; Lin AH; Sun Y; Qian CN; Ma J; Mai HQ; Chen MY
    Oral Oncol; 2018 May; 80():1-8. PubMed ID: 29706183
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction chemotherapy followed by concurrent chemoradiotherapy is benefit for advanced stage nasopharyngeal carcinoma with different nonkeratinizing carcinoma subtypes.
    Zang J; Li C; Xu M; Xu W; Kang X; Wang J; Luo S; Shi M
    Sci Rep; 2018 Sep; 8(1):13318. PubMed ID: 30190563
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Induction plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy in elderly patients with locoregionally advanced nasopharyngeal carcinoma.
    Chen L; Li K; Li Q; Ji P; Huang C; Tang L
    Radiother Oncol; 2024 Nov; 200():110497. PubMed ID: 39191301
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era.
    Li PJ; Mo HY; Luo DH; Hu WH; Jin T
    Oral Oncol; 2018 Oct; 85():95-100. PubMed ID: 30220326
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Radiotherapy Alone Versus Concurrent or Adjuvant Chemoradiotherapy for Nasopharyngeal Carcinoma Patients with Negative Epstein-Barr Virus DNA after Induction Chemotherapy.
    Kong F; Pan G; Du C; Hu C; Ying H
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980576
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Individualized induction chemotherapy by pre-treatment plasma Epstein-Barr viral DNA in advanced nasopharyngeal carcinoma.
    Zhang J; Peng H; Li WF; Zhang Y; Liu LZ; Tian L; Lin AH; Sun Y; Ma J
    BMC Cancer; 2018 Dec; 18(1):1276. PubMed ID: 30567511
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
    Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
    Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparing the efficacy of induction-concurrent with concurrent-adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: a propensity score matching analysis.
    Wu LR; Jiang XS; Song X; Yu HL; Fan YX; Wang FJ; Huang SF; Guo WJ; He X; Liu JY
    Oncotarget; 2017 Oct; 8(45):79953-79963. PubMed ID: 29108377
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Adjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Long-term results of a phase 3 multicentre randomised controlled trial.
    Chen L; Hu CS; Chen XZ; Hu GQ; Cheng ZB; Sun Y; Li WX; Chen YY; Xie FY; Liang SB; Chen Y; Xu TT; Li B; Long GX; Wang SY; Zheng BM; Guo Y; Sun Y; Mao YP; Tang LL; Chen YM; Liu MZ; Ma J
    Eur J Cancer; 2017 Apr; 75():150-158. PubMed ID: 28235726
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Final results of a randomized phase III trial of induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in patients with stage IVA and IVB nasopharyngeal carcinoma-Taiwan Cooperative Oncology Group (TCOG) 1303 Study.
    Hong RL; Hsiao CF; Ting LL; Ko JY; Wang CW; Chang JTC; Lou PJ; Wang HM; Tsai MH; Lai SC; Liu TW
    Ann Oncol; 2018 Sep; 29(9):1972-1979. PubMed ID: 30016391
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Wang Q; Xu G; Xia Y; Zuo J; Zeng G; Xue Z; Cao R; Xiong W; Li W
    Oral Oncol; 2020 Dec; 111():104925. PubMed ID: 32721816
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Can Epstein-Barr virus-deoxyribonucleic acid load after induction chemotherapy combined with American Joint Committee on Cancer stage determine the chemotherapy intensity of locally advanced nasopharyngeal carcinoma?
    Zhang Q; Peng ZW; Gu ZS; Wang Y; He F; Zhao WB; Luo W; Mei YY
    Cancer Med; 2023 Jan; 12(1):223-235. PubMed ID: 35674137
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy of treatment patterns based on concurrent chemoradiotherapy in patients with stage IIB cervical squamous cell carcinoma.
    Pan XB; Lu Y; Wei YS; Yao DS
    BMC Cancer; 2024 Jan; 24(1):106. PubMed ID: 38238689
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Survival of stage II nasopharyngeal carcinoma patients with or without concurrent chemotherapy: A propensity score matching study.
    Liu DH; Zhou XY; Pan YG; Chen S; Ye ZH; Chen GD
    Cancer Med; 2020 Feb; 9(4):1287-1297. PubMed ID: 31859464
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
    Wang C; Tang X; Wang J; Song J; Xu Y
    Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Survival benefit of induction chemotherapy in treatment for stage III or IV locally advanced nasopharyngeal carcinoma - An updated meta-analysis and systematic review.
    Hu T; Fang L; Shi L; Wang W; Huang Y
    Am J Otolaryngol; 2021; 42(5):102973. PubMed ID: 33812206
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy and safety of a treatment in patients with locoregionally advanced nasopharyngeal carcinoma (LANC) involving carotid artery invasion.
    Liu K; Wang Y; Ma L; Yang S; Zhang X
    Eur Arch Otorhinolaryngol; 2022 Dec; 279(12):5791-5799. PubMed ID: 35918541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.